(Q77636849)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

title

Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference

M Bialer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

L Arcavi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

S Sussan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

A Volosov

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

A Yacobi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

D Moros

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

B Levitt

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

A Laor

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

publication date

1 November 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

page(s)

371-378

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

Assessment of rate of absorption in bioequivalence studies

7 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Steady state pharmacokinetics of conventional versus controlled-release carbamazepine in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

A comparison of the efficacy and tolerability of controlled-release carbamazepine with conventional carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Secondary metrics for the assessment of bioequivalence

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Carbamazepine toxicity resulting from generic substitution

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Application of moment analysis in assessing rates of absorption for bioequivalency studies

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Comparison of statistical moment parameters to Cmax and tmax for detecting differences in in vivo dissolution rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Pharmacokinetic criteria for the evaluation of retard formulations.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Therapeutic bioequivalency study of brand name versus generic carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Carbamazepine (CBZ) controlled release compared with conventional CBZ: a controlled study of attention and vigilance in children with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Mean apical concentration and duration in the comparative bioavailability of slowly absorbed and eliminated drug preparations.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Impact of generic substitution of anticonvulsants on the treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Generic versus branded carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

An analysis of variance test for normality (complete samples)

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Controversies in Bioequivalence Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Pharmacokinetic characterization of controlled-release formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy. The Tegretol OROS Osmotic Release Delivery System Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Carbamazepine and its epoxide: relation of plasma levels to toxicity and seizure control

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2898%2900064-3

7 January 2021

10.1016/S0920-1211(98)00064-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9839777%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference